ClinicalTrials.gg
CompletedNCT00978172Updated Sep 16, 2009

Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria

A Phase 4 interventional study of artesunate and mefloquine in Malaria, sponsored by Mepha Ltd.. Completed at 1 site in Cameroon. Per ClinicalTrials.gov, last updated 2009-09-16.

Sponsored by Mepha Ltd. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
220
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies testing artesunate in Malaria — none open to participants now, none under way, none of them phase 3. Artesunate · Malaria.

Enrollment
40th of 66
220 · median 290
Started
2007
with 5 others
Phase 4
27 of 68
none open now
Registered
35th of 68
by date

Among the 68 studies testing artesunate in Malaria, this one is the 40th largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2007, is one of 27 in phase 4, and was the 35th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

None of the 68 studies testing artesunate in Malaria is open now. The open studies under Malaria, anywhere →

About artesunate

Artesunate: first FDA approval 2020 (ARTESUNATE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 68 studies testing artesunate in Malaria as a file.
02

Study summary

The present study aims to investigate and to assess possible neurological and neuropsychiatric events in young children in west Africa with uncomplicated P. falciparum malaria after a 3-day treatment of Artequin Paediatric under "real life conditions."

Read the detailed description

The study aims investigating the safety profile of Artequin Paediatric in a 3-day treatment of children with uncomplicated P. falciparum malaria under "real life conditions" in West Africa. Important parameters, such as concomitant medication, the patient's medical history and diseases, differential WBC counts, the presence of parasitaemia as well as the patient's compliance are evaluated. Detailed recording of possible AEs and SAEs enable additionally an assessment of the safety and effectiveness of Artequin Paediatric over a period of 63 days following treatment initiation. The present study primarily serves to detect and assess possible neuropsychiatric and neurological events in young children using a standardized questionnaire and axamination.

03

Conditions studied

  • Malaria

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight from ≥ 10 kg to ≤ 20 kg.
  • Presence of acute uncomplicated P. falciparum malaria with a diagnosis confirmed by a positive blood smear with asexual forms of P. falciparum only.
  • Counts of asexual forms of P. falciparum: 2'000 to 250'000 parasites per µL of blood.
  • Presence of fever defined as axillary temperature of ≥37.5 °C (≥ 38 °C if oral, rectal or tympanic temperature) or a history of fever within the last 24 hours.
  • Written provided by the patient and parent or guardian. If the person is unable to write, thumb print witnessed consent is permitted.
  • Willingness and ability of the patient and the parent or guardian to comply with study protocol for the duration of the study.
  • Patients who are able to take oral medication.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe/complicated malaria as defined by the World Health Organization, 2000, Severe falciparum malaria (18).
  • Known history or evidence of disorders: neurological, psychiatric (depression, psychosis or schizophrenia), cardiovascular (including arrhythmia), pulmonary, metabolic, gastrointestinal, endocrine diseases or .
  • Patients with a history of epilepsy or of convulsions.
  • Patients who received any anti-malarial treatment within 7 days prior to enrolment including any substance with anti-malarial activity, e.g. antibiotics)or treatment with mefloquine within 30 days prior to enrolment.
  • Patients with a or allergic reaction to artemisinins or mefloquine or any chemically related entity (e.g. quinine).
  • Patients who participated in any drug trial within 30 days prior to enrolment.
  • Patients with vomiting 3 or more times within 24 hours of enrolment or more than 3 copious liquid stools within 24 hours.
  • Patients with known renal impairment.
  • Patients who do require parenteral treatment.
  • Patients who have had a splenectomy.
  • Known patients and who are receiving immunosuppressive agents and/or patients with known (HIV) infection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
220 participants (actual)

Interventions

  • Drugartesunate and mefloquine

    Drug pages: Artesunate · Mefloquine

    artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally

    Also known as: Artequin[TM] Paediatric stickpack

06

What researchers measure

Primary outcomes

  1. To assess the neuropsychiatric and neurological safety of a fixed-dose combination of artesunate and mefloquine (Artequin Paediatric) in the treatment of children (>=10kg to <=20kg body weight) with uncomplicated P. falciparum malaria

    Time frame: Baseline (day1), day 7, day 28, day 63

Secondary outcomes

  1. To determine further safety and effectiveness parameters of Artequin Paediatric

    Time frame: Baseline (day1), day 4, day7, day 28, day 63

07

Study locations

1 site
  • Centre Mère et Enfant, Fondation Chantal Biya
    Yaounde, BP 1936, Cameroon
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2009
First posted
Sep 16, 2009
Start
Dec 2007
CompletionActual
Mar 2009
Last update
Sep 16, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00978172
Lead sponsor
Mepha Ltd.
Collaborators
Centre Mère et Enfant de la Fondation Chantal Biya
First posted
Sep 16, 2009
Start date
Dec 2007
Completion
Mar 2009
Last update
Sep 16, 2009

Study contacts

Felix Tietche, Prof
principal investigator · Faculty of Medicine and Biomedical Sciences University of Yaounde (Cameroon)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Artesunate · Mefloquine

Start the discussion